SCHEMBL24331552

SCHEMBL24331552

c1ccc2c(N3CCN(c4ccc5oc(N6CCOCC6)nc5c4)CC3)c[nH]c2c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ELANE P08246 1/20 0.46
▸ PRKDC P78527 2/20 0.46
▸ XRCC6 P12956 1/20 0.46
▸ XRCC5 P13010 1/20 0.46
▸ FAAH O00519 2/20 0.44
▸ MAPT P10636 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ PDGFRB P09619 1/20 0.43
▸ FGFR1 P11362 1/20 0.43
▸ FLT1 P17948 1/20 0.43
▸ HCRTR2 O43614 1/20 0.42
▸ ITK Q08881 1/20 0.41
▸ JAK1 P23458 1/20 0.41
▸ JAK3 P52333 1/20 0.41
▸ ALDH1A1 P00352 1/20 0.40
▸ MGLL Q99685 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30611169 1.00 ELANE (0.46) ELANEPRKDCXRCC6XRCC5FAAH
SCHEMBL30611150 0.84 CYP2D6 (0.48) ELANEPRKDCXRCC6XRCC5FAAH
SCHEMBL24331227 0.84 CYP2D6 (0.48) ELANEPRKDCXRCC6XRCC5FAAH
SCHEMBL24329854 0.83 KDM4E (0.46) ELANEKDM4EPDGFRBJAK1JAK3
SCHEMBL26912673 0.82 MAPT (0.59) MAPTKDM4ETHRBPDGFRBITK
SCHEMBL24330414 0.82 FGFR1 (0.53) ELANEPRKDCXRCC6XRCC5FAAH
SCHEMBL30611151 0.82 FGFR1 (0.53) ELANEPRKDCXRCC6XRCC5FAAH
SCHEMBL30611141 0.81 CYP2D6 (0.52) ELANEPRKDCXRCC6XRCC5FAAH
SCHEMBL24331243 0.81 CYP2D6 (0.52) ELANEPRKDCXRCC6XRCC5FAAH
SCHEMBL24331545 0.79 PDGFRB (0.48) ELANEPRKDCXRCC6XRCC5FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230391774-A1 Novel Compounds AC IMMUNE SA (CH) 2023-12-07 — — US claimed
CN-116568684-A Novel compounds AC免疫有限公司 2023-08-08 — — CN claimed
US-20230391774-A1 Novel Compounds AC IMMUNE SA (CH) 2023-12-07 — — US disclosed
CN-116568684-A Novel compounds AC免疫有限公司 2023-08-08 — — CN disclosed
WO-2022078971-A1 NOVEL COMPOUNDS AC IMMUNE SA (CH) 2022-04-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391774-A1 Novel Compounds MAPT, PSEN2, PSEN1 ELANE 2173/4885PRKDC 3877/4885XRCC6 3133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback